A tumor-suppressor role for FBXO11 was first discovered in DLBCL, where it is mutated in up to 10% of cases and selectively ubiquitinates the germinal-center transcription factor BCL6 leading to its degradation10. The gene discussed is FBXO11; the disease is neoplasm.